CN108542826B - 一种含亲水性角蛋白的活肤晚霜及其制备方法 - Google Patents
一种含亲水性角蛋白的活肤晚霜及其制备方法 Download PDFInfo
- Publication number
- CN108542826B CN108542826B CN201810540575.0A CN201810540575A CN108542826B CN 108542826 B CN108542826 B CN 108542826B CN 201810540575 A CN201810540575 A CN 201810540575A CN 108542826 B CN108542826 B CN 108542826B
- Authority
- CN
- China
- Prior art keywords
- parts
- skin
- keratin
- night cream
- hydrophilic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010076876 Keratins Proteins 0.000 title claims abstract description 73
- 102000011782 Keratins Human genes 0.000 title claims abstract description 73
- 239000006071 cream Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 54
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 37
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 28
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 21
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 21
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 21
- 229940016667 resveratrol Drugs 0.000 claims abstract description 21
- 229930182490 saponin Natural products 0.000 claims abstract description 19
- 150000007949 saponins Chemical class 0.000 claims abstract description 19
- 229920001184 polypeptide Polymers 0.000 claims abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 17
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000011187 glycerol Nutrition 0.000 claims abstract description 15
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 15
- 241001061264 Astragalus Species 0.000 claims abstract description 14
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 14
- 235000006533 astragalus Nutrition 0.000 claims abstract description 14
- 239000004205 dimethyl polysiloxane Substances 0.000 claims abstract description 14
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims abstract description 14
- -1 polydimethylsiloxane Polymers 0.000 claims abstract description 14
- 210000004233 talus Anatomy 0.000 claims abstract description 14
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 14
- 229940046009 vitamin E Drugs 0.000 claims abstract description 14
- 239000011709 vitamin E Substances 0.000 claims abstract description 14
- 235000019864 coconut oil Nutrition 0.000 claims abstract description 13
- 239000003240 coconut oil Substances 0.000 claims abstract description 13
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 9
- 239000012736 aqueous medium Substances 0.000 claims abstract description 9
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 8
- 239000002537 cosmetic Substances 0.000 claims abstract description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 235000017709 saponins Nutrition 0.000 claims description 18
- 230000037303 wrinkles Effects 0.000 claims description 18
- 239000003995 emulsifying agent Substances 0.000 claims description 17
- 239000012071 phase Substances 0.000 claims description 17
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 14
- 229960005323 phenoxyethanol Drugs 0.000 claims description 14
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 11
- 239000003921 oil Substances 0.000 claims description 9
- 235000019198 oils Nutrition 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical group C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 8
- 229940086555 cyclomethicone Drugs 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 7
- 235000002639 sodium chloride Nutrition 0.000 claims description 7
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims description 5
- 101001050275 Homo sapiens Keratin, type I cuticular Ha1 Proteins 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 3
- 238000004945 emulsification Methods 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 235000013772 propylene glycol Nutrition 0.000 claims description 3
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 229960002668 sodium chloride Drugs 0.000 claims description 2
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims 3
- 229940100524 ethylhexylglycerin Drugs 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000004888 barrier function Effects 0.000 abstract description 8
- 235000012041 food component Nutrition 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 210000003491 skin Anatomy 0.000 description 64
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 28
- 238000012360 testing method Methods 0.000 description 24
- 230000000694 effects Effects 0.000 description 19
- 239000000306 component Substances 0.000 description 14
- 239000011570 nicotinamide Substances 0.000 description 14
- 229960003966 nicotinamide Drugs 0.000 description 14
- 235000005152 nicotinamide Nutrition 0.000 description 14
- 239000000047 product Substances 0.000 description 11
- 230000004060 metabolic process Effects 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000001815 facial effect Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 230000008591 skin barrier function Effects 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 239000009636 Huang Qi Substances 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000001153 anti-wrinkle effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 229940107666 astragalus root Drugs 0.000 description 3
- 238000005282 brightening Methods 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002344 surface layer Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 2
- VEVYMLNYMULSMS-AVGNSLFASA-N Ser-Tyr-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O VEVYMLNYMULSMS-AVGNSLFASA-N 0.000 description 2
- OQWNEUXPKHIEJO-NRPADANISA-N Val-Glu-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N OQWNEUXPKHIEJO-NRPADANISA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical group O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 2
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- OQCPATDFWYYDDX-HGNGGELXSA-N Ala-Gln-His Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O OQCPATDFWYYDDX-HGNGGELXSA-N 0.000 description 1
- GGNHBHYDMUDXQB-KBIXCLLPSA-N Ala-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)N GGNHBHYDMUDXQB-KBIXCLLPSA-N 0.000 description 1
- FFZJHQODAYHGPO-KZVJFYERSA-N Ala-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N FFZJHQODAYHGPO-KZVJFYERSA-N 0.000 description 1
- SGYSTDWPNPKJPP-GUBZILKMSA-N Arg-Ala-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SGYSTDWPNPKJPP-GUBZILKMSA-N 0.000 description 1
- UXJCMQFPDWCHKX-DCAQKATOSA-N Arg-Arg-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UXJCMQFPDWCHKX-DCAQKATOSA-N 0.000 description 1
- NABSCJGZKWSNHX-RCWTZXSCSA-N Arg-Arg-Thr Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N NABSCJGZKWSNHX-RCWTZXSCSA-N 0.000 description 1
- VNFWDYWTSHFRRG-SRVKXCTJSA-N Arg-Gln-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O VNFWDYWTSHFRRG-SRVKXCTJSA-N 0.000 description 1
- KMFPQTITXUKJOV-DCAQKATOSA-N Arg-Ser-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O KMFPQTITXUKJOV-DCAQKATOSA-N 0.000 description 1
- DDBMKOCQWNFDBH-RHYQMDGZSA-N Arg-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O DDBMKOCQWNFDBH-RHYQMDGZSA-N 0.000 description 1
- QHUOOCKNNURZSL-IHRRRGAJSA-N Arg-Tyr-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O QHUOOCKNNURZSL-IHRRRGAJSA-N 0.000 description 1
- LEFKSBYHUGUWLP-ACZMJKKPSA-N Asn-Ala-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LEFKSBYHUGUWLP-ACZMJKKPSA-N 0.000 description 1
- JEPNYDRDYNSFIU-QXEWZRGKSA-N Asn-Arg-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(N)=O)C(O)=O JEPNYDRDYNSFIU-QXEWZRGKSA-N 0.000 description 1
- NNMUHYLAYUSTTN-FXQIFTODSA-N Asn-Gln-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O NNMUHYLAYUSTTN-FXQIFTODSA-N 0.000 description 1
- NLRJGXZWTKXRHP-DCAQKATOSA-N Asn-Leu-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NLRJGXZWTKXRHP-DCAQKATOSA-N 0.000 description 1
- LZLCLRQMUQWUHJ-GUBZILKMSA-N Asn-Lys-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N LZLCLRQMUQWUHJ-GUBZILKMSA-N 0.000 description 1
- MYRLSKYSMXNLLA-LAEOZQHASA-N Asn-Val-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MYRLSKYSMXNLLA-LAEOZQHASA-N 0.000 description 1
- IXIWEFWRKIUMQX-DCAQKATOSA-N Asp-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O IXIWEFWRKIUMQX-DCAQKATOSA-N 0.000 description 1
- YNQIDCRRTWGHJD-ZLUOBGJFSA-N Asp-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(O)=O YNQIDCRRTWGHJD-ZLUOBGJFSA-N 0.000 description 1
- SVFOIXMRMLROHO-SRVKXCTJSA-N Asp-Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SVFOIXMRMLROHO-SRVKXCTJSA-N 0.000 description 1
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- UCSXXFRXHGUXCQ-SRVKXCTJSA-N Cys-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CS)N UCSXXFRXHGUXCQ-SRVKXCTJSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- PKVWNYGXMNWJSI-CIUDSAMLSA-N Gln-Gln-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKVWNYGXMNWJSI-CIUDSAMLSA-N 0.000 description 1
- MADFVRSKEIEZHZ-DCAQKATOSA-N Gln-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N MADFVRSKEIEZHZ-DCAQKATOSA-N 0.000 description 1
- HYPVLWGNBIYTNA-GUBZILKMSA-N Gln-Leu-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O HYPVLWGNBIYTNA-GUBZILKMSA-N 0.000 description 1
- LGIKBBLQVSWUGK-DCAQKATOSA-N Gln-Leu-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LGIKBBLQVSWUGK-DCAQKATOSA-N 0.000 description 1
- CAXXTYYGFYTBPV-IUCAKERBSA-N Gln-Leu-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CAXXTYYGFYTBPV-IUCAKERBSA-N 0.000 description 1
- IOFDDSNZJDIGPB-GVXVVHGQSA-N Gln-Leu-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IOFDDSNZJDIGPB-GVXVVHGQSA-N 0.000 description 1
- LPIKVBWNNVFHCQ-GUBZILKMSA-N Gln-Ser-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LPIKVBWNNVFHCQ-GUBZILKMSA-N 0.000 description 1
- WIMVKDYAKRAUCG-IHRRRGAJSA-N Gln-Tyr-Glu Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O WIMVKDYAKRAUCG-IHRRRGAJSA-N 0.000 description 1
- OGMQXTXGLDNBSS-FXQIFTODSA-N Glu-Ala-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O OGMQXTXGLDNBSS-FXQIFTODSA-N 0.000 description 1
- DIXKFOPPGWKZLY-CIUDSAMLSA-N Glu-Arg-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O DIXKFOPPGWKZLY-CIUDSAMLSA-N 0.000 description 1
- RCCDHXSRMWCOOY-GUBZILKMSA-N Glu-Arg-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O RCCDHXSRMWCOOY-GUBZILKMSA-N 0.000 description 1
- WOSRKEJQESVHGA-CIUDSAMLSA-N Glu-Arg-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O WOSRKEJQESVHGA-CIUDSAMLSA-N 0.000 description 1
- VAZZOGXDUQSVQF-NUMRIWBASA-N Glu-Asn-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N)O VAZZOGXDUQSVQF-NUMRIWBASA-N 0.000 description 1
- NADWTMLCUDMDQI-ACZMJKKPSA-N Glu-Asp-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N NADWTMLCUDMDQI-ACZMJKKPSA-N 0.000 description 1
- XHUCVVHRLNPZSZ-CIUDSAMLSA-N Glu-Gln-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XHUCVVHRLNPZSZ-CIUDSAMLSA-N 0.000 description 1
- QIQABBIDHGQXGA-ZPFDUUQYSA-N Glu-Ile-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O QIQABBIDHGQXGA-ZPFDUUQYSA-N 0.000 description 1
- CXRWMMRLEMVSEH-PEFMBERDSA-N Glu-Ile-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O CXRWMMRLEMVSEH-PEFMBERDSA-N 0.000 description 1
- DNPCBMNFQVTHMA-DCAQKATOSA-N Glu-Leu-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O DNPCBMNFQVTHMA-DCAQKATOSA-N 0.000 description 1
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 1
- SUIAHERNFYRBDZ-GVXVVHGQSA-N Glu-Lys-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O SUIAHERNFYRBDZ-GVXVVHGQSA-N 0.000 description 1
- SYWCGQOIIARSIX-SRVKXCTJSA-N Glu-Pro-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O SYWCGQOIIARSIX-SRVKXCTJSA-N 0.000 description 1
- MRWYPDWDZSLWJM-ACZMJKKPSA-N Glu-Ser-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O MRWYPDWDZSLWJM-ACZMJKKPSA-N 0.000 description 1
- JVYNYWXHZWVJEF-NUMRIWBASA-N Glu-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O JVYNYWXHZWVJEF-NUMRIWBASA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- UAVQIQOOBXFKRC-BYULHYEWSA-N Ile-Asn-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O UAVQIQOOBXFKRC-BYULHYEWSA-N 0.000 description 1
- LPXHYGGZJOCAFR-MNXVOIDGSA-N Ile-Glu-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N LPXHYGGZJOCAFR-MNXVOIDGSA-N 0.000 description 1
- SAEWJTCJQVZQNZ-IUKAMOBKSA-N Ile-Thr-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SAEWJTCJQVZQNZ-IUKAMOBKSA-N 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- CNNQBZRGQATKNY-DCAQKATOSA-N Leu-Arg-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N CNNQBZRGQATKNY-DCAQKATOSA-N 0.000 description 1
- KKXDHFKZWKLYGB-GUBZILKMSA-N Leu-Asn-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N KKXDHFKZWKLYGB-GUBZILKMSA-N 0.000 description 1
- HUEBCHPSXSQUGN-GARJFASQSA-N Leu-Cys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N HUEBCHPSXSQUGN-GARJFASQSA-N 0.000 description 1
- KAFOIVJDVSZUMD-UHFFFAOYSA-N Leu-Gln-Gln Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-UHFFFAOYSA-N 0.000 description 1
- YVKSMSDXKMSIRX-GUBZILKMSA-N Leu-Glu-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O YVKSMSDXKMSIRX-GUBZILKMSA-N 0.000 description 1
- WMTOVWLLDGQGCV-GUBZILKMSA-N Leu-Glu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N WMTOVWLLDGQGCV-GUBZILKMSA-N 0.000 description 1
- HPBCTWSUJOGJSH-MNXVOIDGSA-N Leu-Glu-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HPBCTWSUJOGJSH-MNXVOIDGSA-N 0.000 description 1
- WQWSMEOYXJTFRU-GUBZILKMSA-N Leu-Glu-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O WQWSMEOYXJTFRU-GUBZILKMSA-N 0.000 description 1
- AVEGDIAXTDVBJS-XUXIUFHCSA-N Leu-Ile-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AVEGDIAXTDVBJS-XUXIUFHCSA-N 0.000 description 1
- PDQDCFBVYXEFSD-SRVKXCTJSA-N Leu-Leu-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O PDQDCFBVYXEFSD-SRVKXCTJSA-N 0.000 description 1
- HVHRPWQEQHIQJF-AVGNSLFASA-N Leu-Lys-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HVHRPWQEQHIQJF-AVGNSLFASA-N 0.000 description 1
- LFSQWRSVPNKJGP-WDCWCFNPSA-N Leu-Thr-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(O)=O LFSQWRSVPNKJGP-WDCWCFNPSA-N 0.000 description 1
- MYZMQWHPDAYKIE-SRVKXCTJSA-N Lys-Leu-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O MYZMQWHPDAYKIE-SRVKXCTJSA-N 0.000 description 1
- DLCAXBGXGOVUCD-PPCPHDFISA-N Lys-Thr-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DLCAXBGXGOVUCD-PPCPHDFISA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- WXWDPFVKQRVJBJ-CIUDSAMLSA-N Ser-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N WXWDPFVKQRVJBJ-CIUDSAMLSA-N 0.000 description 1
- BGOWRLSWJCVYAQ-CIUDSAMLSA-N Ser-Asp-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BGOWRLSWJCVYAQ-CIUDSAMLSA-N 0.000 description 1
- OJPHFSOMBZKQKQ-GUBZILKMSA-N Ser-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CO OJPHFSOMBZKQKQ-GUBZILKMSA-N 0.000 description 1
- HVKMTOIAYDOJPL-NRPADANISA-N Ser-Gln-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O HVKMTOIAYDOJPL-NRPADANISA-N 0.000 description 1
- SMIDBHKWSYUBRZ-ACZMJKKPSA-N Ser-Glu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O SMIDBHKWSYUBRZ-ACZMJKKPSA-N 0.000 description 1
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 1
- GYDFRTRSSXOZCR-ACZMJKKPSA-N Ser-Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GYDFRTRSSXOZCR-ACZMJKKPSA-N 0.000 description 1
- ZVBCMFDJIMUELU-BZSNNMDCSA-N Ser-Tyr-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)N ZVBCMFDJIMUELU-BZSNNMDCSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CEXFELBFVHLYDZ-XGEHTFHBSA-N Thr-Arg-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CEXFELBFVHLYDZ-XGEHTFHBSA-N 0.000 description 1
- KGKWKSSSQGGYAU-SUSMZKCASA-N Thr-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KGKWKSSSQGGYAU-SUSMZKCASA-N 0.000 description 1
- LHEZGZQRLDBSRR-WDCWCFNPSA-N Thr-Glu-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LHEZGZQRLDBSRR-WDCWCFNPSA-N 0.000 description 1
- UEFHVUQBYNRNQC-SFJXLCSZSA-N Trp-Phe-Thr Chemical compound C([C@@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=CC=C1 UEFHVUQBYNRNQC-SFJXLCSZSA-N 0.000 description 1
- KEHKBBUYZWAMHL-DZKIICNBSA-N Tyr-Gln-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O KEHKBBUYZWAMHL-DZKIICNBSA-N 0.000 description 1
- QPZMOUMNTGTEFR-ZKWXMUAHSA-N Val-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N QPZMOUMNTGTEFR-ZKWXMUAHSA-N 0.000 description 1
- PVPAOIGJYHVWBT-KKHAAJSZSA-N Val-Asn-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N)O PVPAOIGJYHVWBT-KKHAAJSZSA-N 0.000 description 1
- ISERLACIZUGCDX-ZKWXMUAHSA-N Val-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N ISERLACIZUGCDX-ZKWXMUAHSA-N 0.000 description 1
- TZVUSFMQWPWHON-NHCYSSNCSA-N Val-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N TZVUSFMQWPWHON-NHCYSSNCSA-N 0.000 description 1
- VLDMQVZZWDOKQF-AUTRQRHGSA-N Val-Glu-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N VLDMQVZZWDOKQF-AUTRQRHGSA-N 0.000 description 1
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010001271 arginyl-glutamyl-arginine Proteins 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- DJXAJTDFRRFQDI-UHFFFAOYSA-N silyloxy(silyloxysilyloxysilyloxysilyloxy)silane Chemical compound [SiH3]O[SiH2]O[SiH2]O[SiH2]O[SiH2]O[SiH3] DJXAJTDFRRFQDI-UHFFFAOYSA-N 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
Abstract
本发明属于化妆品领域，具体涉及一种含亲水性角蛋白的活肤晚霜及其制备方法。该含亲水性角蛋白的活肤晚霜按质量份包括以下组分：聚二甲基硅氧烷5～10份、椰子油1～3份、维生素E 0.5～1.5份、烟酰胺2～5份、甘油20～30份、黄芪总皂苷0.3～0.8份、白藜芦醇0.3～0.8份、丙二醇10～15份、二丙二醇8～12份、多肽溶液1～5份、亲水性角蛋白溶液0.5～2份和水介质25～35份。本发明的活肤晚霜保湿效果好，亲水性角蛋白的存在能在皮肤表面形成稳定的屏障，能减少其他营养成分的挥发并进一步促进人体对其他营养成分的吸收。
Description
技术领域
本发明属于化妆品领域，具体涉及一种含亲水性角蛋白的活肤晚霜及其制备方法。
背景技术
皮肤在夜间比白日里更容易流失水分，晚上给皮肤补水更为重要，根据皮肤学专家及皮肤病理学家们长期观察研究发现，晚上11点至凌晨5点是皮肤细胞生长和修复最旺盛的时候，这时候细胞分裂的速度比平时快8倍左右，因而对护肤、滋养品的吸收率特别高。夜晚是生理机能自律调护的休息阶段，这时候最需要的就是滋养肌肤，加速细胞的新陈代谢，修护肌肤白天受到的损害，补充营养，让肌肤变得更有弹性，更加细腻。所以晚霜应运而生，晚霜根据其配方不同，所能达到的护肤效果就不同，如美白、保湿、抗衰老等功能。
申请号为201510310919.5的专利公布了一种晚霜，配方：以100质量份计算，以下各组分质量份：荷荷巴油6.0-7.0，橄榄油1.0-2.0，鲸蜡醇0.5-1.0，羊毛脂10.0-15.0，樱花2.0-3.0，党参1.0-2.0，人参1.0-2.0，蜂蜜10.0-20.0，茉莉精油5.0-8.0，玫瑰精油4.0-5.0，甘油3.0-4.0，香精0.1-0.5，蒸馏水余量。该晚霜起的作用为去除使用者面部皱纹，同时能够长效保持肌肤湿润细腻有光泽。
申请号为201510343731.0的专利公布了一种祛斑晚霜，其由以下重量份数的原料制成：月桂酸酯12-18份，羟甲基纤维素2-6份，单硬脂甘油酯7-9份，乳酸钠3-7份，酵母提取物4-13份，硅油6-10份，竹叶提取物4-8份，羊毛脂1-2份，牛磺酸2-4份，山梨酸钾0.4-0.6份，丙二醇4-6份，硫辛酸0.02-0.04份，金盏花花瓣3-4份，甘草酸二钾2-5份，吡咯烷酮羧酸钠7-14份，水解蚕丝6-12份，葡萄籽油4-10份。该晚霜具有祛斑、美白的效果。
申请号为201710984296.9的专利公开一种清凉抗皱晚霜，由以下成分按重量配比制成：薄荷香油0.3-0.6份、留兰香油0.3-0.6份、羊毛脂8-16份、硬脂酸2-8份、乳化蜡3-10份、三乙胺醇0.1-0.4份、丙二醇2-8、精制水加至100份、香精适量。该晚霜使用后皮肤更加清凉舒爽、滋润抗皱。
虽然，许多晚霜具有良好的滋润效果，但是对于面部的持续护理、营养补充及平衡功能的强化，以及综合有效的解决皮肤的相关问题，尚需要进一步提高。
因此开发一种能够在皮肤表面形成屏障、进行自我修复、减少其他营养成分的挥发并进一步促进人体对其他营养成分吸收的晚霜，已达到综合有效的解决皮肤的各种问题。
发明内容
有鉴于此，本发明的目的在于提供一种含亲水性角蛋白的活肤晚霜，该活肤晚霜保湿效果好，亲水性角蛋白的存在能在皮肤表面形成稳定的屏障，能减少其他营养成分的挥发并进一步促进人体对其他营养成分的吸收。
为实现上述目的，本发明的技术方案为：
一种含亲水性角蛋白的活肤晚霜，按质量份包括以下组分：聚二甲基硅氧烷5-10份、椰子油1-3份、维生素E 0.5-1.5份、烟酰胺2-5份、甘油20-30份、黄芪总皂苷0.3-0.8份、白藜芦醇0.3-0.8份、丙二醇10-15份、二丙二醇8-12份、多肽溶液1-5份、亲水性角蛋白溶液0.5-2份和水介质25-35份。
进一步，所述多肽溶液为含量0.05％的乙酰基六肽。
进一步，所述亲水性角蛋白溶液中亲水性角蛋白为人源K31蛋白的中间片段，其氨基酸序列如SEQ ID NO：1所示；所述亲水性角蛋白溶液中亲水性角蛋白的浓度为10000ppm(1％)。
所述黄芪总皂苷为100％黄芪提取物，不添加任何除黄芪以外的成分，其中主要成分为黄芪甲苷。5％黄芪总皂苷中黄芪甲苷含量应不低于2.0％。
在所述活肤晚霜中核心成分功效为：
维生素E：清除自由基、抗氧化。
烟酰胺：促进新陈代谢，维持皮肤组织的完整性；改善皮肤的屏障作用，降低经表皮失水率、抗炎、减少面部红斑。
黄芪总皂苷：提升皮肤抗病能力，延缓衰老，提亮肤色，去黄气，使皮肤健康有光泽。
白藜芦醇：抗氧化、抗炎、延缓衰老。
多肽溶液：提拉紧致肌肤，减少皱纹。
亲水性角蛋白溶液：保湿和促进皮肤屏障功能的自我修复。能够保持皮肤角质层的含水量在适宜范围内，有效预防干纹、皱纹的产生和促进皮肤表面损伤的自我修复。
本发明的活肤晚霜的活性成分含量较高，质地较滋润，保湿和修复效果好，能对白天受损肌肤进行夜间调理、修护，也可在白天使用，但效果欠佳。
本发明的活肤晚霜中里面添加多个清除自由基和抗氧化的成分，同时加入了烟酰胺以促进新陈代谢，加快表皮角质的更新，皮肤新陈代谢的加快能促进营养成分的吸收。亲水性角蛋白能在皮肤表面形成稳定的屏障，维持皮肤的含水量；烟酰胺还有抗击肌肤炎症的功效，因此烟酰胺与亲水性角蛋白能形成协同作用促进新陈代谢进而促进皮肤表层的自我修复；白藜芦醇有抗炎、抗氧化、延缓衰老的功效，白藜芦醇与亲水性角蛋白能发挥抗氧化、预防干纹、皱纹产生的协同作用。本发明的活肤晚霜中亲水性角蛋白能形成的稳定屏障还能减少其他营养成分的挥发并进一步促进人体对其的吸收。多肽能在补充细胞间质的同时提拉紧致肌肤，减少皱纹的产生。
进一步，所述活肤晚霜按质量份包括以下组分：聚二甲基硅氧烷8份、椰子油2份、维生素E 1份、烟酰胺3份、甘油25份、黄芪总皂苷0.5份、白藜芦醇0.5份、丙二醇12份、二丙二醇10份、多肽溶液3份、亲水性角蛋白溶液1份和水介质29.55份。
进一步，所述活肤晚霜还包括乳化剂1-5份、氯化钠0.3-0.8份、EDTA二钠0.01-0.08份、苯氧乙醇0.5-1份、乙基己基甘油0.05-0.15份的一种或多种。
作为一种优选，所述活肤晚霜还包括乳化剂3份、氯化钠0.5份、EDTA二钠0.05份、苯氧乙醇0.8份、乙基己基甘油0.1份的一种或多种。
作为一种优选，所述乳化剂的成分包括环聚二甲基硅氧烷、PEG-10聚二甲基硅氧烷、还己硅氧烷、有机膨润土、碳酸丙二醇酯的一种或多种。
本发明的目的之二在于提供一种上述含亲水性角蛋白的活肤晚霜的制备方法，包括以下步骤：
1)配置油相：按上述质量份将聚二甲基硅氧烷、椰子油、维生素E、乳化剂混合，在60-70℃使其充分搅拌混合均匀，并用均质机均质使乳化剂充分分散，得油相；
2)配置水相：按上述质量份将黄芪总皂苷、白藜芦醇、丙二醇、二丙二醇、乙基己基甘油、苯氧乙醇、烟酰胺、甘油、氯化钠和EDTA二钠加入水介质中经超声溶解，得水相；
3)在60-70℃条件下，将步骤2)制备的水相加入到步骤1)制备的油相中，搅拌均质至完全乳化后待温度降低到40℃以下，再加入多肽溶液和角蛋白溶液，搅拌均匀得含亲水性角蛋白的活肤晚霜。
作为一种优选，步骤2)中，按质量份先将黄芪总皂苷、白藜芦醇、丙二醇、二丙二醇、乙基己基甘油、苯氧乙醇超声溶解，待溶解完全后继续加入剩余物料，继续超声至所有物料完全溶解，得水相。
黄芪总皂苷微溶于醇，几乎不溶于水；白藜芦醇难溶于水，易溶于乙醇，丙酮等有机溶剂。因此先用丙二醇和二丙二醇溶解以上两个物料。烟酰胺在水或乙醇中易溶，在甘油中溶解，因此用水和甘油溶解烟酰胺。待所有物料均溶解完成后，再混合在一起制得水相。
本发明的目的之三在于提供一种亲水性角蛋白在制备用于含保湿功能化妆品中的应用，所述亲水性角蛋白溶液中亲水性角蛋白为人源K 31蛋白的中间片段，其氨基酸序列如SEQ ID NO：1所示。
本发明的目的还在于提供一种用于促进新陈代谢和促进皮肤自我修复的保湿组合物，由烟酰胺和亲水性角蛋白溶液组成，烟酰胺和亲水性角蛋白溶液的质量比为2-5∶0.5-3；所述亲水性角蛋白溶液中亲水性角蛋白的氨基酸序列如SEQ ID NO：1所示。所述亲水性角蛋白溶液中亲水性角蛋白的浓度为10000ppm(1％)。
本发明的目的还在于提供一种的上述保湿组合物在制备用于促进新陈代谢和促进皮肤自我修复的化妆品中的应用。
亲水性角蛋白能在皮肤表面形成稳定的屏障，维持皮肤的含水量；烟酰胺还有抗击肌肤炎症的功效，因此烟酰胺与亲水性角蛋白能形成协同作用促进新陈代谢进而促进皮肤表层的自我修复。
本发明的目的还在于提供一种用于抗氧化、预防干纹、皱纹产生的保湿组合物，由白藜芦醇和亲水性角蛋白溶液组成，白藜芦醇和亲水性角蛋白溶液的质量比为0.3-0.8∶0.5-2；所述亲水性角蛋白溶液中亲水性角蛋白的氨基酸序列如SEQ ID NO：1所示。所述亲水性角蛋白溶液中亲水性角蛋白的浓度为10000ppm(1％)。
本发明的目的还在于提供一种上述的保湿组合物在制备用于抗氧化、预防干纹、皱纹产生的化妆品中的应用。
亲水性角蛋白能在皮肤表面形成稳定的屏障，维持皮肤的含水量，能有效预防干纹、皱纹的产生和促进皮肤表面损伤的自我修复，白藜芦醇有抗炎、抗氧化、延缓衰老的功效，白藜芦醇与亲水性角蛋白能发挥抗氧化、预防干纹、皱纹产生的协同作用。
本发明的有益效果在于：
1)本发明将含亲水性的角蛋白用在活肤晚霜中，活肤晚霜中亲水性角蛋白能在皮肤表面形成的稳定屏障还能减少其他营养成分的挥发并进一步促进人体对其的吸收，与其他营养成分协同发挥促进新陈代谢进而促进皮肤表层的自我修复、和抗氧化、预防干纹、皱纹产生的作用。
2)本发明提供的含亲水性角蛋白的活肤晚霜的功效有：保湿滋润；对抗皮肤自由基，抗氧化；紧致肌肤，预防皱纹；加速皮肤新陈代谢，提亮肤色；促进皮肤屏障功能的自我修复。
3)本发明提供的制备所述活肤晚霜的制备方法简单，绿色安全，具有良好的工业应用前景。
具体实施方式
以下将对本发明的优选实施例进行详细描述。优选实施例中未注明具体条件的实验方法，通常按照常规条件，所举实施例是为了更好地对本发明的内容进行说明，但并不是本发明的内容仅限于所举实施例。所以熟悉本领域的技术人员根据上述发明内容对实施方案进行非本质的改进和调整，仍属于本发明的保护范围。
实施例1含亲水性角蛋白的活肤晚霜
成分列表：
制备方法包括以下步骤：
1)配置油相：按上述质量份将聚二甲基硅氧烷、椰子油、维生素E、乳化剂混合，在60-70℃使其充分搅拌混合均匀，并用均质机均质使乳化剂充分分散，得油相；
2)配置水相：按上述质量份先将黄芪总皂苷、白藜芦醇、丙二醇、二丙二醇、乙基己基甘油、苯氧乙醇超声溶解，待溶解完全后继续加入剩余物料，继续超声至所有物料完全溶解，得水相；
3)在60-70℃条件下，将步骤2)制备的水相加入到步骤1)制备的油相中，搅拌均质至完全乳化后待温度降低到40℃以下，再加入多肽溶液和角蛋白溶液，搅拌均匀得含亲水性角蛋白的活肤晚霜。
实施例2含亲水性角蛋白的活肤晚霜
成分列表：
| 成分 | 占质量比 |
| 聚二甲基硅氧烷 | 10.00％ |
| 椰子油 | 3.00％ |
| 环聚二甲基硅氧烷 | 3.50％ |
| 维生素E | 1.20％ |
| 水 | 30.05％ |
| 烟酰胺 | 5.00％ |
| 甘油 | 24.00％ |
| 氯化钠 | 0.40％ |
| EDTA二钠 | 0.03％ |
| 苯氧乙醇 | 0.50％ |
| 乙基己基甘油 | 0.12％ |
| 5％黄芪总皂苷 | 0.70％ |
| 白藜芦醇 | 0.70％ |
| 丙二醇 | 10.00％ |
| 二丙二醇 | 8.00％ |
| 多肽溶液 | 2.00％ |
| 亲水性角蛋白溶液 | 0.80％ |
制备方法参照实施例1。
实施例3含亲水性角蛋白的活肤晚霜成分列表：
| 成分 | 占质量比 |
| 聚二甲基硅氧烷 | 9.00％ |
| 椰子油 | 2.00％ |
| 环聚二甲基硅氧烷 | 2.50％ |
| 维生素E | 1.50％ |
| 水 | 28.75％ |
| 烟酰胺 | 2.50％ |
| 甘油 | 22.00％ |
| 氯化钠 | 0.80％ |
| EDTA二钠 | 0.02％ |
| 苯氧乙醇 | 1.00％ |
| 乙基己基甘油 | 0.05％ |
| 5％黄芪总皂苷 | 0.40％ |
| 白藜芦醇 | 0.48％ |
| 丙二醇 | 12.00％ |
| 二丙二醇 | 10.00％ |
| 多肽溶液 | 5.00％ |
| 亲水性角蛋白溶液 | 2.00％ |
制备方法参照实施例1。
实施例4对比例
成分列表：
未添加亲水性角蛋白溶液，制备方法参照实施例1。
实施例5对比例
成分列表：
未添加烟酰胺，制备方法参照实施例1。
实施例6对比例
成分列表：
| 成分 | 占质量比 |
| 聚二甲基硅氧烷 | 8.00％ |
| 椰子油 | 2.00％ |
| 环聚二甲基硅氧烷 | 3.00％ |
| 维生素E | 1.00％ |
| 水 | 31.05％ |
| 烟酰胺 | 3.00％ |
| 甘油 | 25.00％ |
| 氯化钠 | 0.50％ |
| EDTA二钠 | 0.05％ |
| 苯氧乙醇 | 0.80％ |
| 乙基己基甘油 | 0.10％ |
| 5％黄芪总皂苷 | 0.50％ |
| 丙二醇 | 12.00％ |
| 二丙二醇 | 10.00％ |
| 多肽溶液 | 2.00％ |
| 亲水性角蛋白溶液 | 1.00％ |
未添加白藜芦醇，制备方法参照实施例1。
实施例7效果性能指标测试
对实施例1-3及实施例(对比例)4-6制备的晚霜进行效果性能指标的测试。涉及的仪器有：皮肤水分含量测试仪、皮肤水分流失测试仪、皮肤弹性测试仪、皮肤快速光学成像系统。
1.皮肤屏障功能修复评价测试：评价产品使用前，产品使用4周后的皮肤屏障功能修复。招募60名志愿者，女性，18-65岁，面部皮肤屏障功能较差，随机分为6组。测试项目包括：皮肤水分含量测试、皮肤水分流失测试。单侧脸颊用。
平均检测结果见表2：
表2皮肤水分含量和流失测试
2.抗皱功效评价：评价产品使用前、使用7天、15天和30天后的抗皱功效。招募60名志愿者，女性，18-65岁，面部皮肤干燥、眼角皱纹级别2-4(0-7分制)，，单侧眼角用该产品。用3D数字成像技术测量使用该产品后皱纹的体积和深度。：。
平均检测和评价结果：
7天后，该产品使皱纹体积和长度的平均值分别减少22.7％和18.6％。15天和30后，皱纹深度的平均值分别减少17.9％和28.5％。
实施例8实际使用效果
对实施例1-3和实施例(对比例)4-6制备的晚霜进行性能指标的测试，测试指标包括保湿效果测测试、修复效果和炎症性皮肤的改善效果测试。
1、保湿效果的测试方法
1)测试方法：以从市场的A产品为对比产品，随机挑选25-60岁的女性志愿者140名并分为7组，每组20人。受试者晚上清洁脸部后使用，取适量顺着面部肌肤纹理的方向，从内侧往外稍加按压，使用前用皮肤水份仪测试，连续使用本产品7天后，用皮肤水份仪测试对比；
2)测试结果：使用产品7天，7天后，受试者的面部的缺水肌变水润肌得到改善情况，并查看受损皮肤得到修复改善情况，如表1所示。
2、炎症性皮肤的改善效果
以从市场的A产品为对比产品，随机挑选25-60岁的女性志愿者140名并分为7组，每组20人。受试者晚上清洁脸部后使用，连续使用本产品7天，21天后测定使用者的皮肤改善情况，测试条件固定在相对湿度40～60％，室温为25℃下进行。皮肤改善情况见表3。其中，患者皮肤炎症减轻或痊愈、痘印的消除均可认为炎症有所改善。结果见表3。
表3制备的晚霜的性能指标测试结果
由表4数据可以看出，由本发明提供的晚霜对皮肤具有明显改善效果，实施例1-3制备的晚霜均在短期内(7天)即表现出明显的效果。在保湿、受损皮肤得到修复改善和炎症改善率率较市场产品A和对比例4-6均表现出较好的性能，由本申请所提供的晚霜对皮肤具体一定的调节和修复作用，长期使用可改善皮肤抗氧化能力和达到紧致肌肤、提亮肤色的效果，还能有效预防干纹、皱纹的产生和促进皮肤表面损伤的自我修复。
最后说明的是，以上实施例仅用以说明本发明的技术方案而非限制，尽管参照较佳实施例对本发明进行了详细说明，本领域的普通技术人员应当理解，可以对本发明的技术方案进行修改或者等同替换，而不脱离本发明技术方案的宗旨和范围，其均应涵盖在本发明的权利要求范围当中。
<110> 海默斯（重庆）医学生物技术有限公司
<120> 一种含亲水性角蛋白的活肤晚霜及其制备方法
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 311
<212> PRT
<213> Artificial
<220>
<223> 人源K31蛋白的中间片段
<400> 1
Lys Glu Thr Met Gln Phe Leu Asn Asp Arg Leu Ala Ser Tyr Leu
5 10 15
Glu Lys Val Arg Gln Leu Glu Arg Asp Asn Ala Glu Leu Glu Asn
20 25 30
Leu Ile Arg Glu Arg Ser Gln Gln Gln Glu Pro Leu Leu Cys Pro
35 40 45
Ser Tyr Gln Ser Tyr Phe Lys Thr Ile Glu Glu Leu Gln Gln Lys
50 55 60
Ile Leu Cys Thr Lys Ser Glu Asn Ala Arg Leu Val Val Gln Ile
65 70 75
Asp Asn Ala Lys Leu Ala Ala Asp Asp Phe Arg Thr Lys Tyr Gln
80 85 90
Thr Glu Leu Ser Leu Arg Gln Leu Val Glu Ser Asp Ile Asn Gly
95 100 105
Leu Arg Arg Ile Leu Asp Glu Leu Thr Leu Cys Lys Ser Asp Leu
110 115 120
Glu Ala Gln Val Glu Ser Leu Lys Glu Glu Leu Leu Cys Leu Lys
125 130 135
Ser Asn His Glu Gln Glu Val Asn Thr Leu Arg Cys Gln Leu Gly
140 145 150
Asp Arg Leu Asn Val Glu Val Asp Ala Ala Pro Thr Val Asp Leu
155 160 165
Asn Arg Val Leu Asn Glu Thr Arg Ser Gln Tyr Glu Ala Leu Val
170 175 180
Glu Thr Asn Arg Arg Glu Val Glu Gln Trp Phe Thr Thr Gln Thr
185 190 195
Glu Glu Leu Asn Lys Gln Val Val Ser Ser Ser Glu Gln Leu Gln
200 205 210
Ser Tyr Gln Ala Glu Ile Ile Glu Leu Arg Arg Thr Val Asn Ala
215 220 225
Leu Glu Ile Glu Leu Gln Ala Gln His Asn Leu Arg Asp Ser Leu
230 235 240
Glu Asn Thr Leu Thr Glu Ser Glu Ala Arg Tyr Ser Ser Gln Leu
245 250 255
Ser Gln Val Gln Ser Leu Ile Thr Asn Val Glu Ser Gln Leu Ala
260 265 270
Glu Ile Arg Ser Asp Leu Glu Arg Gln Asn Gln Glu Tyr Gln Val
275 280 285
Leu Leu Asp Val Arg Ala Arg Leu Glu Cys Glu Ile Asn Thr Tyr
290 295 300
Arg Ser Leu Leu Glu Ser Glu Asp Cys Asn Leu
305 310
Claims (7)
1. 一种含亲水性角蛋白的活肤晚霜，其中，按质量份由以下组分组成：聚二甲基硅氧烷5~10份、椰子油1~3份、维生素E 0.5~1.5份、烟酰胺2~5份、甘油20~30份、5%黄芪总皂苷0.3~0.8份、白藜芦醇0.3~0.8份、丙二醇10~15份、二丙二醇8~12份、多肽溶液1~5份、亲水性角蛋白溶液0.5~2份、乳化剂1~5份、氯化钠0.3~0.8份、EDTA二钠0.01~0.08份、苯氧乙醇0.5~1份、乙基己基甘油0.05~0.15份和水介质25~35份；其中所述亲水性角蛋白溶液中亲水性角蛋白为人源K31蛋白的中间片段，其氨基酸序列如SEQ ID NO:1所示；所述多肽溶液为含量0.05%的乙酰基六肽；所述亲水性角蛋白溶液中亲水性角蛋白的浓度为10000ppm；所述乳化剂为环聚二甲基硅氧烷。
2. 根据权利要求1所述的含亲水性角蛋白的活肤晚霜，其中，按质量份由以下组分组成：聚二甲基硅氧烷8份、椰子油2份、维生素E 1份、烟酰胺3份、甘油25份、5%黄芪总皂苷0.5份、白藜芦醇0.5份、丙二醇12份、二丙二醇10份、多肽溶液3份、亲水性角蛋白溶液1份、乳化剂3份、氯化钠0.5份、EDTA二钠0.05份、苯氧乙醇0.8份、乙基己基甘油0.1份、和水介质29.55份；所述乳化剂为环聚二甲基硅氧烷。
3. 根据权利要求1所述的含亲水性角蛋白的活肤晚霜，其中，按质量份由以下组分组成：聚二甲基硅氧烷10份、椰子油3份、维生素E 1.2份、烟酰胺5份、甘油24份、5%黄芪总皂苷0.7份、白藜芦醇0.7份、丙二醇10份、二丙二醇8份、多肽溶液2份、亲水性角蛋白溶液0.8份、乳化剂3.5份、氯化钠0.4份、EDTA二钠0.03份、苯氧乙醇0.5份、乙基己基甘油0.12份、和水介质30.05份；所述乳化剂为环聚二甲基硅氧烷。
4. 根据权利要求1所述的含亲水性角蛋白的活肤晚霜，其中，按质量份由以下组分组成：聚二甲基硅氧烷9份、椰子油2份、维生素E 1.5份、烟酰胺2.5份、甘油22份、5%黄芪总皂苷0.4份、白藜芦醇0.48份、丙二醇12份、二丙二醇10份、多肽溶液5份、亲水性角蛋白溶液2份、乳化剂2.5份、氯化钠0.8份、EDTA二钠0.02份、苯氧乙醇1份、乙基己基甘油0.05份、和水介质28.75份；所述乳化剂为环聚二甲基硅氧烷。
5.权利要求1~4任一项所述的含亲水性角蛋白的活肤晚霜的制备方法，其特征在于，包括以下步骤：
1)配置油相：按上述质量份将聚二甲基硅氧烷、椰子油、维生素E、乳化剂混合，在60~70℃使其充分搅拌混合均匀，并用均质机均质使乳化剂充分分散，得油相；
2)配置水相：按上述质量份将黄芪总皂苷、白藜芦醇、丙二醇、二丙二醇、乙基己基甘油、苯氧乙醇、烟酰胺、甘油、氯化钠和EDTA二钠加入水介质中经超声溶解，得水相；
3)在60-70℃条件下，将步骤2)制备的水相加入到步骤1)制备的油相中，搅拌均质至完全乳化后，待温度降低到40℃以下，再加入多肽溶液和角蛋白溶液，搅拌均匀得含亲水性角蛋白的活肤晚霜。
6.如权利要求1-4任一项所述的含亲水性角蛋白的活肤晚霜在制备用于保湿、促进皮肤自我修复、或炎症改善的化妆品中的应用。
7.如权利要求1-4任一项所述的含亲水性角蛋白的活肤晚霜在制备用于预防干纹、皱纹产生的化妆品中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810540575.0A CN108542826B (zh) | 2018-05-30 | 2018-05-30 | 一种含亲水性角蛋白的活肤晚霜及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810540575.0A CN108542826B (zh) | 2018-05-30 | 2018-05-30 | 一种含亲水性角蛋白的活肤晚霜及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108542826A CN108542826A (zh) | 2018-09-18 |
| CN108542826B true CN108542826B (zh) | 2023-06-06 |
Family
ID=63511518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810540575.0A Active CN108542826B (zh) | 2018-05-30 | 2018-05-30 | 一种含亲水性角蛋白的活肤晚霜及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108542826B (zh) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1324850A (zh) * | 2000-05-24 | 2001-12-05 | 上海博德基因开发有限公司 | 一种新的多肽——人角蛋白30.36和编码这种多肽的多核苷酸 |
| CN104946668A (zh) * | 2015-06-29 | 2015-09-30 | 湖南省植物保护研究所 | cry1Ia基因及应用、由其编码的Cry1Ia蛋白及制备方法和应用 |
| CN104971011A (zh) * | 2015-07-13 | 2015-10-14 | 吕铝淼 | 一种抗衰老补水面膜的制备工艺 |
| CN105125429A (zh) * | 2015-07-13 | 2015-12-09 | 吕铝淼 | 一种抗衰老补水面膜 |
| CN105395465A (zh) * | 2015-12-31 | 2016-03-16 | 周雷雷 | 一种保湿美白面霜 |
| CN105724371A (zh) * | 2016-02-29 | 2016-07-06 | 苏州市贝克生物科技有限公司 | 抑菌喷雾及其制备方法 |
| CN107365355B (zh) * | 2017-08-07 | 2020-06-26 | 温州千瑞生物科技有限公司 | 抗皱纹的肽以及包含其的化妆品 |
-
2018
- 2018-05-30 CN CN201810540575.0A patent/CN108542826B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108542826A (zh) | 2018-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104856892B (zh) | 一种富含生长因子的化妆品或护肤品制剂及其制备方法 | |
| JP2021020887A (ja) | 強化されたアンチエイジング化粧品組成物 | |
| CN108969446B (zh) | 一种增强皮肤屏障功能的婴幼儿防皴护肤组合物及其制备方法 | |
| KR102165567B1 (ko) | 피부 보습 효과가 우수한 화장료 조성물 | |
| CN107496201A (zh) | 一种乳化口红及其制备方法 | |
| CN110693807B (zh) | 一种肌底精华液及其制备方法 | |
| CN109481337A (zh) | 一种含神经酰胺的润肤保湿乳及其制备方法 | |
| KR101537063B1 (ko) | 비타민 10가지 성분을 함유한 피부 개선용 조성물 | |
| CN111450010A (zh) | 一种具有抗初老功效的组合物及其在化妆品中的应用 | |
| KR20160141297A (ko) | 피부 탄력에 효과를 갖는 마유를 함유하는 피부 재생용 화장료 조성물 및 이의 제조방법 | |
| CN112137951A (zh) | 一种强韧发丝修复头皮屏障的无硅油透明氨基酸洗发水及其制备方法 | |
| CN113576975A (zh) | 一种易吸收的抗衰老组合物及其制备方法和应用 | |
| CN109350591A (zh) | 一种美颜干面膜及其制备方法 | |
| CN113018230A (zh) | 一种组合物及其制备方法与应用 | |
| CN107854403A (zh) | 一种洁净保湿润肤霜 | |
| CN110840782A (zh) | 一种焕颜净肤面膜组合物及其制备方法 | |
| CN110101591A (zh) | 一种长效保湿组合物及其制备方法和应用 | |
| CN113648241A (zh) | 一种高保湿乳液及其制备方法 | |
| CN113081942A (zh) | 一种含有苹果干细胞的多维水合霜 | |
| CN111265454B (zh) | 一种保湿补水的抗衰老化妆品组合物 | |
| TW202106323A (zh) | 迷迭香癒傷組織萃取物用於製備抑制肌膚老化的組合物之用途以及用以誘導迷迭香癒傷組織的培養基 | |
| CN109260086B (zh) | 一种抗皱精华液、制备方法及其应用 | |
| CN112294739A (zh) | 一种多效美白组合物及其在润肤霜中的应用 | |
| CN107753380A (zh) | 一种眉毛增长促进液配方 | |
| CN108451790B (zh) | 一种含亲水性角蛋白的保湿精华液及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 402760 No. 216 Jianshan Road, Biquan Street, Chongqing (Building 2) Patentee after: HAIMOSI (CHONGQING) MEDICAL BIOTECHNOLOGY CO.,LTD. Country or region after: China Address before: 400000 C3-1-1, COSMO Podium Building, Guanyinqiao, Jiangbei District, Chongqing Patentee before: HAIMOSI (CHONGQING) MEDICAL BIOTECHNOLOGY CO.,LTD. Country or region before: China |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 402760 No. 216 Jianshan Road, Biquan Street, Bishan County, Chongqing (Building 2) Patentee after: HAIMOSI (CHONGQING) MEDICAL BIOTECHNOLOGY CO.,LTD. Country or region after: China Address before: 402760 No. 216 Jianshan Road, Biquan Street, Chongqing (Building 2) Patentee before: HAIMOSI (CHONGQING) MEDICAL BIOTECHNOLOGY CO.,LTD. Country or region before: China |